Finance Home - My Yahoo - Yahoo! - Help

Monday, November 30, 2009, 9:05AM ET - U.S. Markets open in 25 mins.. Dow  1.48% Nasdaq  0.00%

GTC Biotherapeutics, Inc. (GTCB)

On Nov 27: 1.00   0.00 (0.00%)

MORE ON GTCB

Quotes Summary Real-Time Options Historical Prices Charts Interactive Basic Chart Basic Tech. Analysis News & Info Headlines Financial Blogs Company Events Message Board Company Profile Key Statistics SEC Filings Competitors Industry Components Analyst Coverage Analyst Opinion Analyst Estimates Research Reports Star Analysts Ownership Major Holders Insider Transactions Insider Roster Financials Income Statement Balance Sheet Cash Flow

Profile Get Profile for:
GTC Biotherapeutics, Inc. 175 Crossing Boulevard Framingham, MA 01702 United States - Map Phone: 508-620-9700 Fax: 508-370-3797 Web Site: http://www.gtc-bio.com DETAILS   Index Membership: N/A Sector: Healthcare Industry: Biotechnology Full Time Employees: 153 BUSINESS SUMMARY   GTC Biotherapeutics, Inc. develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. GTC’s recombinant human antithrombin, ATryn, has been approved for use in the United States and Europe. ATryn is the first product produced in transgenic animals to be approved for therapeutic use. In addition to ATryn, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa and IX, which are being developed for the treatment of hemophilia. GTC is also developing a portfolio of follow-on biologic monoclonal antibodies and a CD20 antibody with enhanced ADCC (antibody-dependent cell-mediated cytotoxicity). Its intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly suited to enable the development of proteins that are difficult to express in traditional recombinant production systems, as well as proteins that are required in large volumes. The company was founded in 1993 and is based in Framingham, Massachusetts. Key Statistics COMPANY WEBSITES   Home Page Search Yahoo! for: More on GTC Biotherapeutics, Inc.		CORPORATE GOVERNANCE   GTC Biotherapeutics, Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 49.2% of CGQ Universe companies and 25.5% of Pharmaceuticals, Biotechnology & Life Sciences companies. Brought to you by Institutional Shareholder Services. View Financials KEY EXECUTIVES     Pay Exercised Mr. Geoffrey Cox Ph.D., 65 Chairman, Chief Exec. Officer and Pres N/A N/A Mr. John B. Green , 54 Chief Financial Officer, Sr. VP and Treasurer N/A N/A Dr. Harry M. Meade Ph.D., 62 Sr. VP of R&D N/A N/A Mr. Daniel S. Woloshen , 61 Sr. VP and Gen. Counsel N/A N/A Mr. Richard A. Scotland , 53 Sr. VP of Regulatory Affairs $ 264.00K N/A Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year. View Insiders
Add to Portfolio     Set Alert     Email to a Friend Get Profile for Another Symbol: Symbol Lookup • Annual Reports • Sector Analysis